A new oral semaglutide medication has shown promising results in Phase 3 clinical trials for both weight loss and type 2 diabetes management. Developed by Novo Nordisk, the company behind Ozempic and Wegovy, this pill form offers a convenient alternative to injections.

The trial, presented at the American Diabetes Association Scientific Session in Los Angeles, involved 667 participants with obesity but not type 2 diabetes. Those taking the 50mg daily dose of oral semaglutide achieved an average weight loss of 17.4% over 68 weeks, compared to 1.8% in the placebo group. This translates to an average weight loss of 44 pounds for those who completed the trial.

Dr. Robert Gabbay, chief scientific and medical officer for the ADA, expressed enthusiasm about the oral form, stating it "opens up this type of therapy to many more people that could potentially benefit." He highlighted the significance of addressing obesity, a common issue among individuals with type 2 diabetes. The oral medication could be particularly helpful for those hesitant about injections.

Lead study author Dr. Filip Knop emphasized that while participants had obesity, they did not have type 2 diabetes. He noted that in addition to weight loss, semaglutide can reduce cardiovascular disease risk in individuals with diabetes. Dr. Gabbay echoed this, suggesting the oral version may offer similar cardiovascular benefits.

Common side effects were primarily gastrointestinal, similar to those reported with Ozempic and Wegovy. Less common side effects included temporary changes in skin sensation. Following the positive trial results, the drugmakers plan to seek FDA approval.